Date of submission of the HTAC Recommendation: 14 May 2026
Date of notification to HTAC on the SOH decision: 17 August 2026

The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Iopromide (1) 623.40 mg/mL (equivalent to 300 mg iodine) and (2) 768.86 mg/mL (equivalent to 370 mg iodine) in 500 mL in clear glass infusion bottle for use as radiocontrast media through Department of Health (DOH) Department Circular No. 2026 – 0441  “Inclusion of New Formulations and Revision of Existing Formulations of Iopromide in the Philippine National Drug Formulary” published on 20 July 2026.

As final recommendation, the HTA Council recommends the following for government financing: 

• Iopromide  623.40 mg/mL (equivalent to 300 mg iodine), 500 mL clear glass infusion bottle; and,
• Iopromide 768.86 mg/mL (equivalent to 370 mg iodine),  500 mL clear glass infusion bottle.

For further details, please refer to the documents below